These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26507768)

  • 1. Differences in protein binding and excretion of Triapine and its Fe(III) complex.
    Pelivan K; Miklos W; van Schoonhoven S; Koellensperger G; Gille L; Berger W; Heffeter P; Kowol CR; Keppler BK
    J Inorg Biochem; 2016 Jul; 160():61-9. PubMed ID: 26507768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
    Mathuber M; Hager S; Keppler BK; Heffeter P; Kowol CR
    Dalton Trans; 2021 Nov; 50(44):16053-16066. PubMed ID: 34617075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS.
    Pelivan K; Frensemeier L; Karst U; Koellensperger G; Bielec B; Hager S; Heffeter P; Keppler BK; Kowol CR
    Analyst; 2017 Aug; 142(17):3165-3176. PubMed ID: 28745337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation.
    Enyedy ÉA; May NV; Pape VFS; Heffeter P; Szakács G; Keppler BK; Kowol CR
    Dalton Trans; 2020 Dec; 49(46):16887-16902. PubMed ID: 33185224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones.
    Pelivan K; Frensemeier LM; Karst U; Koellensperger G; Heffeter P; Keppler BK; Kowol CR
    Anal Bioanal Chem; 2018 Mar; 410(9):2343-2361. PubMed ID: 29476231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.
    Chen G; Niu C; Yi J; Sun L; Cao H; Fang Y; Jin T; Li Y; Lou C; Kang J; Wei W; Zhu J
    J Med Chem; 2019 Mar; 62(6):3107-3121. PubMed ID: 30835473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
    Popović-Bijelić A; Kowol CR; Lind ME; Luo J; Himo F; Enyedy EA; Arion VB; Gräslund A
    J Inorg Biochem; 2011 Nov; 105(11):1422-31. PubMed ID: 21955844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes.
    Kallus S; Uhlik L; van Schoonhoven S; Pelivan K; Berger W; Enyedy ÉA; Hofmann T; Heffeter P; Kowol CR; Keppler BK
    J Inorg Biochem; 2019 Jan; 190():85-97. PubMed ID: 30384010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.
    Miklos W; Heffeter P; Pirker C; Hager S; Kowol CR; van Schoonhoven S; Stojanovic M; Keppler BK; Berger W
    Oncotarget; 2016 Dec; 7(51):84556-84574. PubMed ID: 27602951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention.
    Kowol CR; Miklos W; Pfaff S; Hager S; Kallus S; Pelivan K; Kubanik M; Enyedy ÉA; Berger W; Heffeter P; Keppler BK
    J Med Chem; 2016 Jul; 59(14):6739-52. PubMed ID: 27336684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration of Fe(3+)-Triapine in BEAS-2B Cells.
    Antholine WE; Myers CR
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
    Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
    Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
    Shao J; Zhou B; Di Bilio AJ; Zhu L; Wang T; Qi C; Shih J; Yen Y
    Mol Cancer Ther; 2006 Mar; 5(3):586-92. PubMed ID: 16546972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
    Miklos W; Pelivan K; Kowol CR; Pirker C; Dornetshuber-Fleiss R; Spitzwieser M; Englinger B; van Schoonhoven S; Cichna-Markl M; Koellensperger G; Keppler BK; Berger W; Heffeter P
    Cancer Lett; 2015 May; 361(1):112-20. PubMed ID: 25749419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
    Ishiguro K; Lin ZP; Penketh PG; Shyam K; Zhu R; Baumann RP; Zhu YL; Sartorelli AC; Rutherford TJ; Ratner ES
    Biochem Pharmacol; 2014 Oct; 91(3):312-22. PubMed ID: 25130544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
    Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.
    Joshi A; Kiesel BF; Chaphekar N; Jones R; Guo J; Kunos CA; Taylor S; Chu E; Venkataramanan R; Beumer JH
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):633-640. PubMed ID: 32989483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.
    Chitambar CR; Antholine WE
    Antioxid Redox Signal; 2013 Mar; 18(8):956-72. PubMed ID: 22900955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.